Publications Office of the EU
Germany-Dresden: Pharmaceutical products - EU tenders
DisplayCustomHeader
Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Germany-Dresden: Pharmaceutical products

  • Awarded
    01/10/2019
  • Today
    13/08/2026
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
IKK classic
Place of performance
NUTS code: Germany
Location of buyer
NUTS code: Germany
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
1.00 EUR
Tender reference number
Not available
Description

The subject of this contract is the grant by Amgen GmbH of discounts pursuant to Paragraph 130a(8) of the SGB V for the medicinal product Parsabiv® containing the active substance Etelcalcetid (ATC code: H05BX04) for the period 1.11.2019 to 31.10.2021.

Submission Method
Not available
Tenders may be submitted
Not applicable
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
Award method
Lowest price
Estimated value
Not available
Final contracted value
1.00 EUR
Award of contract
Official name: Amgen GmbH
Postal address: Riesstraße 24
Town: München
Postal code: 80992
Country: DEU
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.